Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxel
Journal
Anticancer Research
Journal Volume
20
Journal Issue
2 B
Pages
1159-1161
Date Issued
2000
Author(s)
Abstract
Paclitaxel was recently recognized as an active chemotherapeutic agent for acquired immunodeficiency syndrome (AIDS)-associated Kaposi's sarcoma (KS). However, the best way to administer paclitaxel in AIDS-KS patients remains unknown. Herein, we reported an AIDS-associated KS patient whose disease progressed on the first-line chemotherapy with doxorubicin and bleomycin, but later responded well to weekly 1-hour infusion of 70 mg/m2 paclitaxel. It is particular noteworthy that this weekly dosing schedule resulted in almost negligible toxicities. The authors suggested a prospective study of weekly paclitacel for AIDS-KS should be started as soon as possible.
SDGs
Other Subjects
bleomycin; doxorubicin; etoposide; paclitaxel; vincristine; acquired immune deficiency syndrome; adult; article; case report; human; Kaposi sarcoma; male; priority journal; side effect; Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Agents, Phytogenic; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Paclitaxel; Ranitidine; Sarcoma, Kaposi
Type
journal article